Table 1. Demographic and clinical characteristics of the enrolled ACS patients.
| Characteristics | Patients (n = 176) |
| Male | 140 (79.55%) |
| Age, yrs | 59.91 ± 10.54 |
| BMI, kg/m2 | 25.75 ± 2.78 |
| Cardiovascular risk factor | |
| Current smoker | 80 (45.45%) |
| Hypertension | 101 (57.39%) |
| Diabetes | 57 (32.39%) |
| Chronic renal failure | 2 (1.14%) |
| Hypercholesterolemia | 56 (31.82%) |
| Other medical history | |
| Prior MI | 28 (15.91%) |
| Prior PCI | 50 (28.41%) |
| Prior CABG | 4 (2.27%) |
| Final diagnosis of ACS | |
| ST-elevation MI | 31 (17.61%) |
| Non–ST-elevation MI | 10 (5.68%) |
| Unstable angina | 135 (76.70%) |
| PCI with coronary stent placement | 156 (88.64%) |
| Laboratory evaluation | |
| LVEF, % | 57.71 ± 7.57 |
| Platelet count, × 105/µL | 224.26 ± 63.21 |
| Total cholesterol, mmol/L | 3.96 ± 1.15 |
| Triglycerides, mmol/L | 1.79 ± 1.68 |
| HDL-C, mmol/L | 1.04 ± 0.29 |
| LDL-C, mmol/L | 2.36 ± 0.93 |
| Creatinie, µmol/L | 77.75 ± 19.69 |
| Antithrombotic treatment in hospital | |
| Aspirin | 172 (97.73%) |
| Glycoprotein IIb/IIIa inhibitor | 94 (53.41%) |
| Heparin | 138 (78.41%) |
| Other medication administered in hospital | |
| ARB | 30 (17.05%) |
| ACE inhibitors | 43 (24.43%) |
| Beta-blockers | 138 (78.41%) |
| CCBs | 62 (35.23%) |
| Statins | 171 (97.16%) |
| Diuretics | 8 (4.55%) |
| Nitrates | 103 (58.52%) |
| Proton pump inhibitor | 22 (12.50%) |
Data are presented as n (%) or median ± SD. ACE: angiotensin-converting enzyme; ACS: acute coronary syndrome; ARB: angiotensin receptor bloker; BMI: body mass index; CABG: coronary artery bypass grafting; CCBs: calcium channel blockers; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; LVEF: left ventricular ejection fraction; MI: myocardiac infarction; PCI: percutaneous coronary intervention.